Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) ...

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

Researchers from the City of Hope and Memorial Sloan Kettering (MSK) Cancer Center, US, have developed a tool named ...

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...